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PML-RAR induces a block of hematopoietic differentiation and
acute promyelocytic leukemia. This block is based on its capacity to
inactivate target genes by recruiting histone deacetylase (HDAC)
and DNA methyltransferase activities. Here we report that MBD1,
a member of a conserved family of proteins able to bind methyl-
ated DNA, cooperates with PML-RAR in transcriptional repression
and cellular transformation. PML-RAR recruits MBD1 to its target
promoter through an HDAC3-mediated mechanism. Binding of
HDAC3 and MBD1 is not confined to the promoter region but
instead is spread over the locus. Knock-down of HDAC3 expression
by RNA interference in acute promyelocytic leukemia cells allevi-
ates PML-RAR-induced promoter silencing. We further demon-
strate that retroviral expression of dominant-negative mutants of
MBD1 in hematopoietic precursors compromises the ability of
PML-RAR to block their differentiation and thus restored cell
differentiation. Our results demonstrate that PML-RAR functions
by recruiting an HDAC3–MBD1 complex that contributes to the
establishment and maintenance of the silenced chromatin state.
chromatin  epigenetics  leukemia
In mammalian cells, DNAmethylation occurs predominantly atCpG dinucleotides, which are distributed unevenly and are
underrepresented in the genome. Clusters of usually unmethyl-
ated CpGs (termed CpG islands) are found in many promoter
regions (reviewed in ref. 1). Changes in DNA methylation
leading to aberrant gene silencing have been demonstrated in
several human cancers (2). Hypermethylation of promoters was
demonstrated to be a frequent mechanism leading to the inac-
tivation of tumor suppressor genes (3).
DNA methylation leads to gene silencing by means of two
distinct mechanisms: (i) methylation at CpG sites that prevents
binding of transcription factors and (ii) recognition of mCpGs by
a family of methyl-CpG binding proteins (MBD). Among these
proteins, MBD1 affects chromatin structure and gene silencing
through a yet-unknown mechanism that likely involves histone
deacetylases (HDACs) (4).
Acute promyelocytic leukemia (APL) is characterized by the
15;17 chromosome translocation (5). The t(15,17), which in-
volves promyelocytic leukemia (PML) on chromosome 15 and
the retinoic acid (RA)  receptor (RAR) on chromosome 17,
generates the chimeric PML-RAR gene. In the absence of RA,
wild-type RARs bind to specific DNA sequences called RA
responsive elements (RARE) and are able to repress transcrip-
tion by recruiting corepressor complexes such as SMRTNCoR
HDAC (6, 7). Physiological concentrations of RA trigger the
dissociation of corepressor complexes and allow for the recruit-
ment of several coactivators, including histone acetylases. Con-
sequentially, RA treatment leads to transcriptional activation.
Finely tuned expression of RA-responsive genes is necessary for
the appropriate differentiation of myeloid cell lineages. In
contrast to wild-type RAR, the transforming protein PML-
RAR is rendered insensitive to physiological concentrations of
RA that would usually trigger transcriptional activation. Because
of its oligomerization state (8), PML-RAR forms stable com-
plexes with corepressors and with DNA methyltransferases
(DNMTs) to target promoters (9), functioning as a constitutive
and potent transcriptional repressor of RARE-containing
genes. It is thus commonly accepted that APL is caused by the
repressive function of PML-RAR. Treatment of APL patients
with higher pharmacological doses of RA forces the release of
corepressor complexes from promoters targeted by PML-
RAR, thus promoting partial transcriptional derepression
(10, 11).
Here we show that MBD1 and PML-RAR are both required
for complete silencing of PML-RAR target genes. PML-
RAR indirectly recruits MBD1 to its target promoter through
an HDAC3-mediated mechanism. Mutations in the MBD do-
main and transrepression domain (TRD) of MBD1 restore
transcriptional activity and prevent the PML-RAR-induced
hematopoietic differentiation block. Together these results iden-
tify MBD1 as a critical mediator of PML-RAR-induced gene
silencing subsequent to promoter hypermethylation.
Results
MBD1 Cooperates with PML-RAR in Repressing Promoter Activity.
The oncogenic protein PML-RAR induces promoter hyper-
methylation at CpG dinucleotides by direct recruitment of
DNMT enzymes (9). Because methylated CpGs are potential
docking sites for the binding of MBD proteins, we wanted to
investigate the role of MBD proteins in the PML-RAR-
mediated transcriptional silencing. In PML-RAR-expressing
cells, such as the hematopoietic precursor U937-PR9 cells and
NB4 cells, MBD1 is the most abundant of the various MBDs
(data not shown). Based on these results, we explored the
possibility that MBD1 contributes directly to PML-RAR gene
repression. For this purpose, we used the reporter plasmid
pRAR2-luc, which contains the firefly luciferase gene driven
by a 5-kbp fragment of human RAR2 promoter (9). After
transient transfection, the RAR2 gene promoter was silenced
only when PML-RAR was expressed at high concentrations
(Fig. 1A, lanes 1–3). We next investigated the contribution, if
any, of MBD1 in the regulation of the RAR2 promoter.
Although neither high nor low concentrations of MBD1 alone
influenced RAR2 transcription (Fig. 1A, lanes 4 and 5),
coexpression of MBD1 with suboptimal amounts of PML-
RAR dramatically repressed the RAR2 promoter (Fig. 1A,
lane 6). Strikingly, a promoter previously methylated in vitro by
SssI DNA methylase was similarly repressed in the presence of
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either MBD1 or PML-RAR (Fig. 1A, lanes 10–12). The
synergistic repression mediated by MBD1 and PML-RAR was
partially reversed by treating cells with trichostatin A (TSA) or
5-Aza-dC, inhibitors of HDACs and DNMTs, respectively (Fig.
1B, lanes 3 and 4). Notably, combination of both drugs com-
pletely restored RAR2 promoter activity (Fig. 1B, lane 5),
suggesting that PML-RAR-mediated repression involves his-
tone deacetylation as well as CpG methylation, with subsequent
binding of MBD1.
We have previously shown that PML-RAR causes RAR2
promoter hypermethylation (9) (see also Fig. 5B, which is published
as supporting information on thePNASweb site).We thus analyzed
the contribution of MBD1 in PML-RAR-induced DNA methyl-
ation. Ectopic expression of PML-RAR recapitulated pRAR2-
luc hypermethylation (Fig. 5A). Interestingly, simultaneous expres-
sion of suboptimal concentration of PML-RAR (which alone has
little to no effect on CpG methylation) together with MBD1
restored RAR2 hypermethylation. However, combination of
5-Aza-dC and TSA almost completely prevented promoter meth-
ylation under similar conditions (Fig. 5A).
To understand whether PML-RAR binding to the RAR2
promoter is a prerequisite for the synergistic repression with
MBD1, we introduced three point mutations into the first half of
the RARE, creating the RARE reporter construct (Fig. 5D).
It has been previously shown that these mutations impair the
functionality of a murine RARE (12).
The down-mutation of RARE (RARE) not only completely
abolished PML-RAR-mediated repression of the RAR2 pro-
moter but also prevented its activation upon RA administration
(Fig. 5E). Moreover, the ability of MBD1 to repress promoter
activity synergistically with PML-RAR was strictly dependent
on the presence of an intact RARE (Fig. 5F). Importantly, the
integrity of the PML-RAR binding site was also a prerequisite
for the induction of promoter methylation (Fig. 5C). Interest-
ingly, MBD1 alone was able to repress the RARE promoter
when it had been previously methylated in vitro, suggesting that
MBD1 can efficiently repress transcription once mCpGs are
provided. Together, these results demonstrate that the repres-
sion of the RAR2 promoter, mediated by PML-RAR and
MBD1, is an active and specific mechanism, relying on binding
of PML-RAR to RARE within the target promoter, with
subsequent induction of promoter methylation and recruitment
of MBD1.
Efficient MBD1 Corepression Activity Depends on the Integrity of both
MBD1 and TRDs.We next wanted to study the contribution to gene
silencing of the two well characterized domains of MBD1, the
N-terminal methyl-CpG binding domain (MBD) and the C-
terminal TRD (Fig. 1C). We generated MBD1 mutants in which
either Arg-22 or Asp-32 was substituted with alanine. These
particular amino acid substitutions were previously shown to
abrogate the ability of the isolated MBD domain to bind to
methylated DNA (13, 14). Each of the mutations in the MBD
domain reduced the ability of MBD1 to corepress promoter
activity with PML-RAR (Fig. 1D), indicating that binding
of MBD1 to mCpGs is required to fully silence methylated
promoters.
We next asked whether mutations in the TRD could also
interfere with the ability of MBD1 to synergize with PML-
RAR in gene repression. Bird and collaborators (15) identified
the amino acids that are critical for the TRD to act as a
transcriptional repressor. Based on these findings, we tested two
mutant proteins, containing conversions of either isoleucine-527
or leucine-530 to arginine in their TRD, for their ability to
repress promoter activity. Similar to the alterations in the MBD
domain, these mutations reduced the repressive potential of
MBD1 and allowed restoration of transcription from the
RAR2 promoter (Fig. 1D). A double-mutant MBD1 protein,
defective in both MBD and TRDs (such as R22A and I527R or
R22A and L530R) was completely unable to repress the RAR2
promoter, suggesting that each of the two MBD1 domains
analyzed in this study independently cooperates with PML-
RAR in promoter silencing. All mutant proteins were ex-
pressed in the cell to a similar degree (Fig. 1D Inset).
HDAC3 Corepressor Complex Bridges PML-RAR and MBD1. It has
been shown that both PML-RAR and MBDs proteins are
associated with a TSA-sensitive deacetylase activity that is an
important component of the repression mechanism (11, 15, 16).
We thus predicted that an HDAC enzyme could interact with
both proteins simultaneously. Because recent studies have sug-
Fig. 1. MBD1 synergizes with PML-RAR to repress RAR2 promoter activity.
(A) Effect of MBD1 on PML-RAR-mediated repression of RAR2. 293T cells
were transfected with a reporter construct containing the human RAR2
promoter upstream of the luciferase cDNA (0.5 g) and expression vectors for
PML-RAR (10 ng and 1 g) and MBD1 (10 ng and 500 ng). Where indicated,
the reporter construct was methylated in vitrowith SssI before addition. Error
bars represent the standard deviation from the mean for triplicate experi-
ments. (B) Effect of DNA methylation and HDAC inhibitors on transcriptional
repression by MBD1. TSA (100 nM) or 5-Aza-dC (1 M), or a combination of
these, was added 20 and 36 h, respectively, before the reporter assay was
performed as described inA. Error bars represent the standard deviation from
the mean for triplicate experiments. (C) Structure of MBD1. (D) Effect of the
mutated MBD1 on PML-RAR-mediated repression. Luciferase assay was per-
formed as inA by using expression plasmids for PML-RAR (10 ng), MBD1 (100
ng), and MBD1 mutants (100 ng). Error bars represent the standard deviation
from the mean for triplicate experiments. (Inset) Wild-type and mutant forms
of MBD1 are expressed at equal levels.
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gested that the PML-RAR adapter proteins N-CoR and SMRT
exist in a stable complex together with HDAC3 (17), we
transiently transfected 293T cells with PML-RAR and Flag-
tagged HDAC3 (F-HDAC3). After immunoprecipitation with
anti-FLAG antibody, we found that HDAC3 was specifically
associated with PML-RAR (Fig. 2A). Next, we analyzed the
HDAC3–MBD1 interaction (Fig. 2B). Cells were cotransfected
with F-HDAC3 and either wild-type MBD1 or MBD1 double
mutant (MBD1-dm, R22AI527R), as indicated. Immunopre-
cipitation results revealed that MBD1 associated with HDAC3
and that this association required the integrity of the TRD of
MBD1. In contrast, mutations in theMBD domain (e.g., MBD1–
R22A) did not affect MBD1–HDAC3 associations (data not
shown). To determine the regions of HDAC3 that are crucial to
the interaction with MBD1, GST-fused deletion mutants (or
GST alone as a control) of HDAC3 were incubated with
[35S]methionine-labeled MBD1, produced by in vitro translation
in a reticulocyte lysate. MBD1 was found to interact with the
N-terminal region of GST-HDAC3 but neither with the C-
terminal region nor with GST polypeptides alone (Fig. 6A, which
is published as supporting information on the PNAS web site).
To further confirm these results, several deletion mutants of
FLAG-HDAC3 were expressed in 293T cells together with
MBD1. Immunoprecipitation experiments revealed that the
N-terminal region of HDAC3 mediates the interaction with
MBD1 (data not shown).
Given the interaction between PML-RAR and HDAC3, and
between HDAC3 and MBD1, we tested whether PML-RAR is
associated with MBD1. In 293T cells, MBD1 could be copre-
cipitated with PML-RAR (Fig. 2C), and, likewise, PML-
RAR could be coprecipitated with MBD1 (data not shown).
The interaction resisted the presence of ethidium bromide in the
precipitation reaction, thus excluding the possibility of a DNA-
mediated protein association (data not shown). Little to no
coprecipitation with PML-RAR was detected of a MBD1
protein mutated in the TRD, such as MBD1–I527R mutant
(data not shown) or MBD1-dm (Fig. 2C). In contrast, a MBD1
protein bearing a mutation only in its MBD domain (R22A) was
not altered in its ability to interact with PML-RAR (data not
shown). Thus, PML-RAR can associate with MBD1, and this
association requires the TRD.
We next wanted to identify which of the PML-RARmoieties
mediates the interaction with MBD1. Association of MBD1 and
RAR or C-PML (which represents the PML part retained in
the translocation) was analyzed by transient transfection exper-
iments by using 293T cells. We additionally included in this study
the chimeric protein p53-RAR (which contains the p53 tet-
ramerization domain fused to RAR), because it has been shown
to behave like PML-RAR in its capacity to block hematopoietic
differentiation (8). Results from the corresponding coimmuno-
precipitations revealed the existence of a stable complex of
MBD1 with RAR (and p53-RAR) (Fig. 6D) but not with
C-PML (Fig. 6E), suggesting that recruitment of MBD1 by
PML-RAR is mediated by its RAR moiety.
The PML-RAR–MBD1 association could be either direct or
mediated through a common interacting partner, such as
HDAC3. To analyze this association, we treated 293T cells with
RA. The presence of this ligand at pharmacological doses is
known to cause a conformational change in PML-RAR protein
that leads to the release of the HDAC–corepressor complex,
concomitantly with recruitment of coactivators (8). RA induced
the release of MBD1 along with that of HDAC3 from PML-
RAR (Fig. 2D), and the association between HDAC3 and
MBD1 persisted even in the presence of RA (Fig. 5G). Thus,
MBD1 association with PML-RAR depends on the simulta-
neous presence of HDAC complex, making it likely that HDAC3
bridges the two proteins.
To investigate whether PML-RAR associates with endoge-
nous MBD1 and HDAC3, we performed coimmunoprecipita-
tion experiments using lysates from either U937-PR9 cells or
patient-derived NB4 cells. Immunoblot analysis of anti-PML-
RAR immunoprecipitates revealed the existence of endoge-
nous complexes of PML-RAR with MBD1 and with HDAC3
(Fig. 2E). Reverse experiments demonstrated that endogenous
MBD1 associated with HDAC3 and PML-RAR (Fig. 2F).
Together, these data strongly suggest that MBD1 and HDAC3
are found in complexes with PML-RAR.
HDAC3 Participates in PML-RAR-Dependent Repression of the En-
dogenous RAR2 Promoter in APL Cells. Because HDAC3 appears
to have an important structural role in the assembly of the
PML-RAR repressor complex, we wondered whether HDAC3
could participate directly in gene silencing.We used interference
RNA to reduce the expression of endogenous HDAC3 in NB4
leukemic cells. The sequence-specific short hairpin RNA vector
pRS-HDAC3 reduced endogenous HDAC3 protein levels in
human NB4 APL (Figs. 3A and 7A, which is published as
supporting information on the PNAS web site). Under these
conditions, endogenous RAR2 mRNA was induced (Fig. 3C),
concomitantly with an increase of acetylation of histone H3 tails
(Fig. 3B).
MBD1 Associates with Methylated RAR2 Promoter in Vivo. To
investigate whether PML-RAR-mediated CpGs methylation
creates docking sites for MBD1 at the endogenous RAR2
Fig. 2. HDAC3 bridges PML-RAR and MBD1. (A) Interaction between
PML-RAR and HDAC3. 293T cells were transfected with PML-RAR and
FLAG-HDAC3 expression vectors, and extracts were immunoprecipitated with
anti-FLAG antibody. Western blots of input lysate or of immunoprecipitates
were analyzed by using antisera against RAR or FLAG. Note that Flag-HADC3
comigrates with a nonspecific band (indicated by an asterisk) but is clearly seen
above background levels. (B) Interaction between MBD1 and HDAC3. Cells
were transfected with MBD1, MBD1-dm (MBD1 R22AI527R), and FLAG-
HDAC3 expression vectors, and extracts were immunoprecipitated with anti-
FLAG antibody. Immunocomplexes were detected by Western blot as in A. (C)
Interaction between MBD1 and PML-RAR. Cells were transfected with MBD1,
MBD1-dm, and PML-RAR expression vectors, and extracts were immunopre-
cipitated with anti-PML (PGM3) antibody. (D) RA disrupts the interaction
between PML-RAR and MBD1. 293T cells were transfected with MBD1 and
PML-RAR expression vectors, and extracts underwent immunoprecipitation
with an anti-PML (PGM3) antibody. Where indicated, cells were treated with
RA (1 mM) 5 h before the immunoprecipitation was performed. (E and F)
Endogenous interaction among PML-RAR, HDAC3, and MBD1. Cell extracts
from NB4 were immunoprecipitated by using either PGM3 or anti-MBD1
antibody.
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promoter, we performed chromatin immunoprecipitation
(ChIP) experiments. In agreement with previous reports (9),
PML-RAR was constitutively bound to the RAR2 promoter
sequence, regardless of the presence of RA (Figs. 3D and 8,
which is published as supporting information on the PNAS web
site). After equivalent ChIP analysis, MBD1 and HDAC3 were
also found to be associated to RAR2 promoter in untreated
cells. In RA-treated cells, MBD1 and HDAC3 were substantially
decreased in the promoter region, whereas histone H3 acetyla-
tion increased significantly (Fig. 3D). To study the kinetics of
MBD1 recruitment to PML-RAR-methylated gene, we per-
formed ChIP experiments in U937-PR9 cells, where PML-
RAR expression is controlled by a Zn-inducible promoter (11).
In these cells, PML-RAR expression leads to a time-dependent
accumulation of mCpGs on the endogenous RAR2 gene and
to its transcriptional silencing. MBD1 was strongly associated
with RAR2 only in those cells in which PML-RAR had been
expressed for 24 h (Figs. 3E and 7B). No enrichment was
detected by using unrelated antibodies (data not shown). Inter-
estingly, whereas PML-RAR binding was restricted to the
promoter region harboring the RARE, MBD1 was also found
outside the promoter (Fig. 3E).
Taken together, our results show a correlation among PML-
RAR expression, promoter hypermethylation, and MBD1 oc-
cupancy of RAR2 promoterexon regions and suggest that
PML-RAR (by means of DNMT recruitment) creates docking
sites for MBD1 on its target promoter.
MBD1 Is Required for the Transforming Properties of PML-RAR.
Because MBD1 synergizes with PML-RAR in promoter re-
pression, we next wanted to investigate whether MBD1 likewise
plays a role during the PML-RAR-induced differentiation
block and whether MBD1 mutants could interfere with such a
process. After Zn-induced expression of PML-RAR, U937-
PR9 cells become refractory to VDTGF differentiation stim-
uli, as measured by the expression of the CD14 differentiation
marker (Fig. 4A, lane 2 versus lane 4). We cloned the wild type
as well as the previously generated MBD1 mutants into a
retroviral vector and used these to infect U937-PR9 cells. After
selection, U937-PR9 cells were exposed to Zn for 16 h to induce
PML-RAR expression with subsequent treatment with VD
TGF for 36 h. As expected, PML-RAR blocked differentia-
tion of control cells (i.e., either not infected or infected with the
empty viruses) by 70%. Overexpression of wild-type MBD1
further enhanced the ability of PML-RAR to prevent cell
differentiation. Strikingly, overexpression of MBD1-dm (R22A
I527R) drastically inhibited the ability of PML-RAR to block
hematopoietic differentiation as measured by FACS analysis of
surface differentiation marker CD14 (Fig. 4A, lane 20). We also
tested the consequence of the expression of MBD1 variants with
single point mutation. Although all of these mutants reduced the
PML-RAR block, they were not able to completely relieve it
(Fig. 4A, lanes 12 and 16, and data not shown), similar to what
was observed for promoter activity levels (Fig. 1D). Taken
together, our data indicate that, in hematopoietic precursors, the
association of MBD1 with methylated PML-RAR-target pro-
moters is required to fully prevent cell differentiation. Expres-
sion of a mutated MBD1 that has lost the ability to bind DNA
and to interact with HDAC3 interferes with the PML-RAR-
induced differentiation block.
Discussion
In this report we show that MBD1 is required for silencing the
PML-RAR target promoter RAR2. After PML-RAR-
induced promoter hypermethylation, MBD1 is recruited to and
remains associated with the silenced RAR2 promoter. Muta-
tions in the MBD and TRDs of MBD1 restore RAR2 tran-
scriptional activity and prevent PML-RAR-induced hemato-
Fig. 3. Binding of PML-RAR and corepressors to the endogenous RAR2 promoter. (A) Western blot analysis of total cell lysates derived from mock and HDAC3
interference RNA APL cells. Human NB4 leukemic cells were infected with a retroviral construct generating HDAC3-specific small hairpin RNA (pRS HDAC3) or
the empty vector (pRS) and selected with puromycin for 3 days. Equal amounts of cell extract from mock and interference RNA cells were blotted with antibodies
indicated. (B) Knock-down of HDAC3 in APL cells affects RAR2 H3 acetylation levels. HDAC3 interference RNA cells (pRS HDAC3) or control cell (pRS) were
subjected to ChIP analysis, as indicated. The promoter of RAR2 was amplified with real-time PCR. Error bars indicate the standard deviation obtained from three
independent experiments. (C) Knock-down of HDAC3 in APL cells affects RAR2 promoter activity. Total RNA was prepared from cells as in A, and RARb2 gene
expression was analyzed relative to GAPDH control by quantitative real-time PCR. Results are expressed as the mean  SEM of two independent experiments
performed in duplicate. (D) RA induces release of the PML-RAR corerepressor complex. NB4 cells were treated or not with RA (1M) for 24 h and then subjected
to ChIP analysis, as indicated. The promoter of RAR2 was amplified with real-time PCR. Error bars indicate the standard deviation obtained from three to five
independent experiments. (E) PML-RAR recruits MBD1 to the RAR2 5 region. U937-PR9 cells were treated with Zn (0 h, 4 h, and 24 h) and then subjected to
ChIP analysis. The promoter region and exon of RAR2 were amplified with real-time PCR. Error bars indicate the standard deviation obtained from three
independent experiments.
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poietic differentiation block. We provide evidence that HDAC3
is a common interactor for both PML-RAR and MBD1. APL
cells knocked down for HDAC3 are impaired in PML-RAR-
mediated gene silencing. Our findings demonstrate (i) a target-
ing mechanism for MBD recruitment by an oncogenic transcrip-
tion factor, (ii) a direct role of MBD1 and HDAC3 in promoter
silencing and in leukemia progression, and (iii) a time-dependent
spreading of MBD1 occupancy outside of the promoter region.
MBD1 and Chromatin Alterations. Many human cancers are char-
acterized by alterations in the balance of DNA methylation (18,
19). Our results indicate that stable binding of MBD1 to the
RAR2 promoter occurs 24 h after PML-RAR induction,
concurrent with the CpG methylation within the promoter
region and exons. At an earlier time point (4 h) in the absence
of CpG methylation, the association of MBD1 with RAR2 is
confined to the PML-RAR binding region, thus suggesting a
direct recruitment by means of the oncoprotein. The association
between MBD1 and PML-RAR could be essential to increase
the ‘‘local’’ concentration of effectors proteins, thus increasing
the probability of efficient binding of MBD1 to methylated
CpGs. Similar scenarios have been postulated for the Rb
HDACSuv39H1HP1 complex (20) and for the assembly of the
RNA polymerase I complex on ribosomal genes (21). Because
DNA methylation is often altered in cancer, and because MBD
proteins are the functional interpreters of DNA methylation, a
crucial role for MBD proteins in cancer can be postulated.
Previously, it was shown that neither HDAC1 nor HDAC2 is
responsible for MBD1-mediated repression (15). Here we
present evidence that the histone deacetylation-dependent re-
pressor property of MBD1 is due to its interaction with HDAC3.
The TRD of MBD1 and the N-terminal region of HDAC3
mediate this interaction. Several groups have recently demon-
strated that MBD proteins (including MBD1) can establish
interactions with several histone methyltransferases (22, 23) and
DNMTs (24). Given the network of interactions among these
factors, one could envision a model whereby binding of MBD1
plays a pivotal role in both establishing and maintaining epige-
netic modification across the RAR2 locus, with PML-RAR
being the ‘‘initiator’’ factor.
PML-RAR-Mediated Repression. The recruitment of HDAC3 by
PML-RAR is of particular interest because it is found in a tight
complex with the nuclear corepressor SMRTN-CoR (25–28)
and is critical for repression by multiple transcription factors
(29–31). Despite the fact that other HDACs are present in the
corepressor complex, the HDAC activity of the complex as well
as its integrity depend completely on the presence of HDAC3 as
well as its association with SMRTN-CoR (32). Thus, the RAR
moiety of PML-RAR, through direct interactions with SMRT
N-CoR (10, 11), likewise recruits a multiprotein corepressor
complex to its target genes, whereas the PML moiety mediates
the interactions with DNMTs. These data establish a direct
connection between DNA methylation and histone deacetyla-
tion in leukemia and further support the concept of interdepen-
dent processes between these two layers of epigenetic control
(Fig. 4B). At pharmacological doses, RA overcomes this repres-
sion and induces epigenetic modifications at its target loci
through a coordinated down-regulation of cellular DNMT ex-
pression (33) and specific recruitment of coactivators at RARE-
containing genes, such as RAR2 (Fig. 4B). Under this condi-
tion, MBD1 dissociates from target promoters, which is
reminiscent of the dynamic association displayed by MeCP2 to
the BDNF and Hairy2a genes (34–36). However, clinical evi-
dence indicates that RA per se is unable to eradicate the leukemic
clone and to cure this disease. Thus, understanding the molec-
ular mechanism of gene silencing is important for developing
new antileukemic strategies. In the present study we have
demonstrated that MBD1 mutated in both the MBD and TRDs
acted in a dominant-negative manner (Figs. 2B and 4A), because
it impaired the ability of PML-RAR to block hematopoietic
cell differentiation. Our data suggest that MBD1 forms oli-
gomers in the cell nucleus, which would explain its dominant-
negative phenotype, because this mutant could sequester wild-
type MBD1 into nonfunctional complexes (R.V. and L.D.C.,
unpublished data). Because MBD1 is located at the core of the
chromatin structure of methylated DNA regions, the dissocia-
tion of MBD1 (or the prevention of its interaction with HDACs)
might stimulate chromatin remodeling and further release the
molecules packed into the chromatin. Further characterization
of the PML-RAR–corepressor complex, which establishes and
allows spreading of the silenced state, will provide insight into
Fig. 4. MBD1 cooperates with PML-RAR-mediated block of hematopoietic
differentiation. (A) U937-PR9 cells, after retroviral infection with MBD1 and
MBD1 mutants or empty vector, were treated or not with Zn for 16 h, as
indicated. Infected cells were treated either with vitamin D and TGF (blue
bars) or with vehicle alone (ethanol, white bars). Cell differentiation was
evaluated by quantitative expression of CD14 antigen (11). Error bars repre-
sent the standard deviation from the mean for triplicate experiments. (B)
Model of promoter repression and activation mechanisms in leukemia. The
oncoprotein PML-RAR binds to a well defined DNA sequence (5) and recruits
NCoR, which in turn serves as platform for the interaction with HDAC3 and
corepressors. The N-terminal region of HDAC3 is additionally responsible for
the interaction with the TRD of MBD1. Similarly, PML establishes interaction
with DNMTs (9). The activity of these corepressors leads to hypoacetylation of
histone tails, DNA methylation (depicted by green lollipop), and transcrip-
tional silencing. Methylated CpGs are potential docking sites for MBD1, which
can in turn recruit further repressor enzymes. The progression wave of the
proposed mechanism might ‘‘close’’ the chromatin structure and influence
neighboring genes. Administration of RA, alone or in combination with
TSA5-Aza-dC, induces release of the corepressor complex and promotes
recruiting of the coactivators containing histone acetyltransferases (HAT) and
ATP-dependent chromatin remodeling activity (40).
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crosstalk among the different epigenetic layers as well as into the
molecular pathology of leukemia.
Materials and Methods
Plasmids and Oligonucleotides. The plasmid pMBD1GFP was
kindly provided by A. Bird. (Wellcome Trust Centre for Cell
Biology, University of Edinburgh, Edinburgh). MBD1 mutants
were made by introducing point mutations into pMBD1GFP
vector by using the Stratagene mutagenesis kit. Retroviral
expression vectors were generated by subcloning cDNA of all
forms of MBD1 into PINCO (37). The expression vector for
PML-RAR, the RAR2-luc reporter plasmid, and the CMV-
-galactosidase were described in ref. 9. pRS-HDAC3 was
generated by ligating synthetic oligonucleotides against the
target sequence into pRETRO-SUPER. Flag-HDAC3 and
GST-HDAC3 deletion mutants were kindly provided by E. Seto
(H. Lee Moffitt Cancer Center at the University of South
Florida, Tampa) (38). Primer sequences and PCR conditions are
available upon request.
Cell Lines, Transfection, and Retroviral Infection. HEK 293T and
HeLa cells were transfected by standard methods. As an internal
reference for transfection efficiency, 20 ng of the pCMV-Gal
plasmid were also cotransfected. Cell extracts were prepared as
described in ref. 9. PINCO-based and pRS-based retroviruses
were produced by transfected Phoenix packaging cells. The
collected retrovirus was subsequently used to infect NB4 and
U937-PR9 hematopoietic precursor cells.
Immunoprecipitation and ChIP. For immunoprecipitations, anti-
bodies were coupled to protein A Sepharose beads. Cell extracts
were prepared in lysis buffer (50 mM Hepes, pH 7.5150 mM
NaCl1 mM EDTA2.5 mM EGTA0.1% Tween 201 mM
phenylmethylsulfonyl f luoride0.4 units/ml aprotinin and leu-
peptin1 mM NaF0.1 mM NaVO4) and incubated with beads
for 8 h at 4°C. Beads were washed five times with lysis buffer
complemented with additional 150 mM NaCl and 0.1% Nonidet
P-40. Bound proteins were eluted with 2 Laemmli sample
buffer and loaded on SDSPAGE. Input lanes show 5% of
lysates used for precipitation. Antibodies were described previ-
ously (PGM3, ref. 9) or are commercially available (anti-MBD1
from Imgenex, anti-FLAG from Sigma, and anti-HDAC3 from
Abcam).
For ChIP, NB4 or U937-PR9 cells were crosslinked with 1%
formaldehyde (Sigma) at 37°C for 10 min. Cells were rinsed
twice with ice-cold PBS and collected. ChIPs were performed
and analyzed as described in ref. 39. The immunoprecipitated
DNA was quantified by real-time quantitative PCR (Roche
LightCycler). The sequences of the PCR primers are available
upon request.
Cell Differentiation. Differentiation of U937-PR9 cells under the
influence of dihydroxyvitamin D3 (250 ngml) and TGF (1
ngml) was performed as described in ref. 9. The percentage of
differentiated antigen-positive cells and the fluorescence were
analyzed by flow cytometry on Becton Dickinson FACScan with
appropriate antibodies, such as CD14 (BD Biosciences).
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